RNS Number : 5046J
One Health Group PLC
01 December 2025
One Health Group plc
("One Health", the "Company" or the "Group")
Half-year Financial Report
H1 26 Revenue and EBITDA significantly ahead of prior year
Strong growth across all KPIs
One Health Group plc (AIM: OHGR), the independent provider of NHS-funded surgical procedures for patients referred from the NHS through 'Patient Choice', announces it unaudited interim results for the six months to 30 September 2025 ("H1 26"), showing continued growth across all operational and financial key performance indicators, in-line with management expectations.
Key Financial Highlights
H1 26
H1 25
Growth
Revenue
£15.6m
£13.3m
+18%
Gross profit
£3.12m
£2.32m
+35%
UnderlyingEBITDA
£1.18m
£0.96m
+23%
UnderlyingEPS
6.89p1
7.46p
- 8%
Cash balance
£10.9m2
£4.9m
+122%
Interim dividend
2.10p
2.07p
+1%
Operational Highlights
H1 26
H1 25
Growth
New NHS patient referrals
9,111
7,857
+16%
Number of consultations
23,927
19,674
+22%
Number of surgical procedures
4,009
3,427
+17%
Number of consultants (excluding anaesthetists)
803
70
+14%
Number of Outreach Clinics
40
37
+8%
Number of Surgical Operating Facilities
12
10
+20%
1 H1'26 Underlying EPS lower due to 43% more shares in issue following March 2025 AIM IPO
2 Includes AIM IPO proceeds payable to the Company of £5.6 million (net) and after purchasing land for development of the surgical hub
3 22 additional NHS consultants have been onboarded since January 2025
Market overview
· One Health revenue is derived from over 60 NHS commissioning bodies and contracts directly with NHS hospitals, transferring their patients from the national waiting list for faster treatment.
· NHS national waiting lists remain very high (7.39 million at the end of September), impacted by industrial action and record demand despite continued efforts to reduce them.
· 'Patient Choice' actively promoted by the UK Government with increased use of independent sector support cited as one of the key actions to reduce NHS waiting lists.
· Further planned industrial action by NHS staff and pending 'NHS Winter Pressures' likely to impact waiting lists further and increase the need for outsourced, independent capacity.
· The Government manifesto commitments on waiting times will be challenging to achieve without additional support from the independent sector.
Surgical Hub progress
· Approved planning application for the Group's first Surgical Hub in Scunthorpe, Lincolnshire. Acquisition of the land completed (in September), and a highly experienced contractor appointed to project manage the build.
· In the final phase of securing the remaining pre-commencement planning condition signoffs and progressing a wide range of design, procurement and early-stage readiness tasks to maintain an expected one year build time.
· The new surgical hub is expected to deliver significant additional surgical operating capacity on completion and has the potential to increase the profitability of the Group.
· Further geographic locations in underserved areas with high NHS demand are being explored for preliminary assessment of suitability and viability for future surgical hubs.
Outlook
· Good progress being made on sourcing additional independent hospital surgical capacity on a wider geography to support further organic growth in new geographical areas.
· Clear strategy to drive continued organic growth through increased patient referrals, a strong pipeline of new surgeons, and additional surgical capacity in existing and new independent sector hospitals to help deliver on challenging Government Waiting List reduction targets.
· The Company remains well funded to deliver further organic growth and execute the carefully planned roll-out of the first surgical hub to accelerate growth and improve profitability.
· The Board remains confident, with the Company on track to deliver growth at the revenue and underlying EBITDA levels for FY 26, in-line with market expectations3.
3Management understands market forecasts for revenue and underlying EBITDA for FY 26 to be £29.6 million and £2.3 million respectively.
Declaration of Interim Dividend
The Board of Directors has declared an interim dividend at the rate of 2.10p per share, in line with the Board's stated dividend policy, to be paid on 23 January 2026 to shareholders on the register as at close of business on 5 January 2026. The ex-dividend date will be 2 January 2026.
Adam Binns, Chief Executive Officer, commented:
"We are delighted to deliver a strong first half with impressive growth across all key performance metrics and remain on track to meet market expectations for the full year. As a long-standing and trusted provider of support to the NHS we are well-positioned to reduce pressure on the NHS and support Government initiatives to reduce waiting lists, providing free high-quality care at the point of delivery for NHS patients, across areas of the UK that need it the most.
"We continue to work constructively with the local planning department and are in the final phase of securing the remaining pre-commencement planning condition signoffs for the new Surgical Hub, all of which are close to completion, with several conditions already recommended for discharge. The remaining work relates to reaching an agreement on land contamination and remediation strategy, and ecology and biodiversity safeguards.
"To ensure the programme does not lose time while these conditions are finalised, we are progressing a wide range of design, procurement and early-stage readiness tasks and remain confident in meeting our expectation of a one-year build time, whether approval comes before the calendar year end or in early 2026."
Online investor presentation
Derek Bickerstaff, Chairman, and Adam Binns, Chief Executive Officer, will provide an overview of the Company's interim results, key achievements and outlook via a SparkLive Webcast today at 15:00 GMT (Monday, 1 December 2025). The presentation will be followed by a live Q&A where participants will be able to submit questions using the 'Ask a question' button on the webcast page.
Please click on the link below to register for the webcast:
https://sparklive.lseg.com/ONEHEALTHGROUP/events/3c988809-19ad-454c-af31-cfe86bfe7da5/one-health-group-half-year-results-announcement
If you wish to keep up to date on Company news please email: onehealth@walbrookpr.com
This announcement contains inside information for the purposes of the UK Market Abuse Regulation
and the Directors of the Company are responsible for the release of this announcement.
For more information, please contact:
One Health Group plc Derek Bickerstaff, Chairman Adam Binns, CEO
www.onehealth.co.uk/investors Via Walbrook PR
Panmure Liberum (Nominated Adviser and Broker) Emma Earl, Will Goode, Mark Rogers Rupert Dearden
Tel: +44 (0)20 3100 2000
Walbrook PR (Media & Investor Relations) Alice Woodings / Paul McManus / Rachel Broad
About One Health Group plc (www.onehealth.co.uk)
One Health engages 80 NHS Consultants (excluding anaesthetists) who sub-specialise in the various surgeries offered by the Company, through a growing network of community-based outreach clinics and surgical operating locations. One Health continues to deliver strong growth and, in the year, to March 2025 provided much needed care to 17,020 new patients, through over 42,000 consultations and over 7,000 surgical procedures. One Health deploys surgeons and anaesthetists that are mostly employed by the NHS, on a subcontracted basis. It currently works with over 130 professionals across 12 independent hospitals and 40 outreach clinics. Within these community-based outreach clinics all consultations and post operative physiotherapy is delivered where required, reducing patient inconvenience and excess travel.
One Health's activities are focused on areas where NHS patient needs are under-supplied by the local NHS service, population density is relatively high and the level of private medical insurance or the ability to self-fund is relatively low. Currently, the Company's activities are focused in Yorkshire, Lincolnshire, Derbyshire, Nottinghamshire and Leicestershire. Revenue is derived from over 60 NHS commissioning bodies in addition to contracts with local NHS Hospital Trusts to transfer their internal waiting list patients to One Health for quicker treatment.
One Health's business model has focused to date on four main areas: orthopaedics, spine, general surgery and gynaecology, with urology introduced at the end of FY25.
Spine and orthopaedics are particularly attractive areas for One Health as the Directors believe that they benefit from powerful growth drivers in terms of an ageing demographic, physical inactivity and an increasing proportion of the population being categorised as obese. Within orthopaedics, the most common surgeries performed by One Health are knee and hip replacements.
Group Statement of Comprehensive Income
For the period ended 30 September 2025
Notes
6 months ended 30 September 2025 UNAUDITED
6 months ended 30 September 2024 UNAUDITED
Year ended 31 March 2025 AUDITED
£
£
£
TURNOVER
15,636,711
13,296,385
28,381,835
Cost of sales
(12,520,743)
(10,981,259)
(23,029,660)
GROSS PROFIT
3,115,968
2,315,126
5,352,175
Other operating income
45,421
52,491
119,310
Administrative expenses excluding depreciation and other adjusting items
(1,977,128)
(1,407,562)
(3,449,871)
Adjusted EBITDA *
3
1,184,261
960,055
2,021,614
Costs of admission of shares to AIM
-
(50,030)
(399,796)
EBITDA
1,184,261
910,025
1,621,818
Depreciation
(65,463)
(68,172)
(134,359)
OPERATING PROFIT
1,118,798
841,853
1,487,459
-
Finance income
208,001
50,062
147,767
Finance costs
(43,819)
(46,614)
(89,685)
PROFIT BEFORE TAXATION
1,282,980
845,301
1,545,541
Taxation
(337,725)
(180,898)
(467,636)
PROFIT AND TOTAL COMPREHENSIVE INCOME FOR THE FINANCIAL PERIOD
945,255
664,403
1,077,905
Earnings per share
Basic (pence per share)
4
6.89
6.94
10.00
Diluted (pence per share)
3
6.78
6.80
9.81
* Adjusted EBITDA refers to earnings before interest, tax, depreciation and amortisation, share-based payments, costs of admission to the AIM market, and other exceptional items.
Group Statement of Financial Position
As at 30 September 2025
Notes
30 September 2025 UNAUDITED
30 September 2024 UNAUDITED
31 March 2025 AUDITED
£
£
£
NON-CURRENT ASSETS
Property, plant and equipment
5
2,904,754
1,200,923
1,379,858
Investment property
5
1,513,490
1,840,771
1,840,771
4,418,244
3,041,694
3,220,629
CURRENT ASSETS
Trade and other receivables
4,442,621
3,616,388
3,992,978
Restricted cash and cash equivalents
57,746
91
1,170,971
Cash and cash equivalents
10,813,760
4,889,076
10,218,182
15,314,127
8,505,555
15,382,131
TOTAL ASSETS
19,732,371
11,547,249
18,602,760
CURRENT LIABILITIES
Borrowings
(29,388)
(1,128,293)
(25,641)
Trade and other payables
(6,214,906)
(4,415,733)
(5,367,216)
Current tax liabilities
(341,576)
(513,359)
(466,897)
(6,585,870)
(6,057,385)
(5,859,754)
NET CURRENT ASSETS
8,728,257
2,448,170
9,522,377
TOTAL ASSETS LESS CURRENT LIABILITIES
13,146,501
5,489,864
12,743,006
NON-CURRENT LIABILITIES
Borrowings
(1,071,797)
-
(1,089,741)
Deferred tax provision
(119,768)
(79,891)
(96,930)
(1,191,565)
(79,891)
(1,186,671)
TOTAL LIABILITIIES
(7,777,435)
(6,137,276)
(7,046,425)
NET ASSETS
11,954,936
5,409,973
11,556,335
CAPITAL AND RESERVES
Share capital
68,548
52,751
68,548
Share premium account
5,432,223
392,048
5,432,223
Revaluation reserve
94,709
29,454
29,988
Share option reserve
226,989
226,989
226,989
Own shares
(372,408)
(829,117)
(372,408)
Retained earnings
6,504,875
5,537,848
6,170,995
EQUITY
11,954,936
5,409,973
11,556,335
Group Statement of Changes in Equity
For the period ended 30 September 2025
Share capital
Share premium
Revaluation reserve
Share option reserve
Own shares
Retained earnings
Total equity attributable to owners of the parent
£
£
£
£
£
£
£
At 1 April 2024 (unaudited, as presented in interims)
52,751
392,048
28,920
226,989
(829,117)
5,261,541
5,133,132
Adjustment per year end
-
-
-
-
-
(167,576)
(167,576)
At 1 April 2024 (audited)
52,751
392,048
28,920
226,989
(829,117)
5,093,965
4,965,556
Profit and total comprehensive income for the period
-
-
-
-
-
664,403
664,403
Deferred tax on market value of share options
-
-
-
-
-
2,114
2,114
Deferred tax on revalued property
-
-
870
-
-
(870)
-
Transfer of revalued property
-
-
(336)
-
-
336
-
Dividends paid
-
-
-
-
-
(389,676)
(389,676)
Adjustment per year end
-
-
-
-
-
167,576
167,576
At 30 September 2024 (unaudited)
52,751
392,048
29,454
226,989
(829,117)
5,537,848
5,409,973
Profit and total comprehensive income for the period
-
-
-
-
-
245,926
245,926
Issue of share capital
15,797
5,671,342
-
-
-
-
5,687,139
Transaction costs on issue of share capital
-
(631,167)
-
-
-
-
(631,167)
Dividends
-
-
-
-
-
(198,108)
(198,108)
Sale of own shares
-
-
-
-
456,709
714,171
1,170,880
Tax on sale of own shares
-
-
-
-
-
(129,242)
(129,242)
Deferred tax on market value of share options
-
-
-
-
-
934
934
Transfer of depreciation on revalued property
-
-
(336)
-
-
336
-
Transfer of deferred tax on revalued property
-
-
870
-
-
(870)
-
At 31 March 2025 (audited)
68,548
5,432,223
29,988
226,989
(372,408)
6,170,995
11,556,335
At 31 March 2025 (audited)
68,548
5,432,223
29,988
226,989
(372,408)
6,170,995
11,556,335
Profit and total comprehensive income for the period
-
-
-
-
-
945,255
945,255
Reclassification on movement of investment property to PPE
-
-
65,490
-
-
(65,490)
-
Revaluation on transfer
-
-
(850)
-
-
850
-
Deferred tax on PPE
-
-
81
-
-
(81)
-
Deferred tax on SBP
-
-
-
-
-
7,479
7,479
Dividends paid
-
-
-
-
-
(554,133)
(554,133)
At 30 September 2025 (unaudited)
68,548
5,432,223
94,709
226,989
(372,408)
6,504,875
11,954,936
Group Statement of Cashflows
For the period ended 30 September 2025
6 months ended 30 September 2025 UNAUDITED
6 months ended 30 September 2024 UNAUDITED
Year ended 31 March 2025 AUDITED
£
£
£
Cash flows from operating activities:
Profit for the period
945,255
664,403
1,077,905
Adjustments for:
Tax charge
337,715
180,898
467,636
Depreciation charges
65,138
68,172
134,359
Loss on disposal of tangible assets
295
-
(1,365)
Finance costs
43,819
46,614
89,685
Finance income
(208,001)
(50,062)
(147,767)
Costs of fundraising on AIM charged to the income statement
-
-
399,796
(Increase)/decrease in trade and other receivables
(449,641)
(286,153)
(662,744)
Increase in trade and other payables
847,728
41,156
930,453
Cash generated from operations
1,582,308
665,028
2,287,958
Tax paid
(439,660)
(3,103)
(612,048)
Net cash inflow from operating activities
1,142,648
661,925
1,675,910
Cash flows from investing activities
Purchase of tangible fixed assets
(1,263,079)
(19,045)
(264,166)
Proceeds from disposal of tangible assets
-
-
1,365
Interest received
208,001
50,062
147,767
Net cash (used in) investing activities
(1,055,078)
31,017
(115,034)
Cash flow from financing activities Proceeds from issue of shares
-
-
5,687,139
Cost of fundraising charged against share premium
-
-
(631,167)
Cost of fundraising charged against income statement
-
-
(399,796)
Sale of treasury shares
-
-
1,170,873
Repayment of borrowings
(14,197)
(26,400)
(1,080,218)
Proceeds from borrowings
-
-
1,100,000
Interest paid
(36,887)
(46,614)
(89,685)
Equity dividends paid
(554,133)
(389,676)
(587,784)
Net cash from/(used in) financing activities
(605,217)
(462,690)
5,169,362
Increase in cash and cash equivalents
(517,647)
230,252
6,730,238
Cash and cash equivalents at beginning of the period
11,389,153
4,658,915
4,658,915
Cash and cash equivalents at end of the period
10,871,506
4,889,167
11,389,153
Cash included in the above held by the employee benefit trust so restricted to compliant expenditure
57,746
91
1,170,971
Notes to the Interim Statements
For the period ended 30 September 2025
1. General information
One Health Group Plc is a public company limited by shares incorporated in England and Wales. The registered address of the Company is 131 Psalter Lane, Sheffield, South Yorks, S11 8UX. The consolidated financial statements (or "financial statements") incorporate the financial statements of the Company and entities (its subsidiaries) controlled by the Company (collectively comprising the "Group").
The principal activity of the Group is that of the provision of surgical facilities and associated healthcare.
2. Accounting policies
2.1 Basis of preparation
The financial information set out in these interim consolidated financial statements for the six months ended 30 September 2025 is unaudited. The financial information presented are not statutory accounts prepared in accordance with the Companies Act 2006, and are prepared only to comply with AIM requirements for interim reporting. Statutory accounts for the year ended 31 March 2025, on which the auditors gave an audit report which was unqualified and did not contain a statement under Section 498(2) or (3) of the Companies Act 2006, have been filed with the Registrar of Companies.
These financial statements have been prepared in accordance with international accounting standards ("IFRS") as adopted by the United Kingdom ("UK") insofar as these apply to interim financial statements.
The interim consolidated financial statements have been prepared using consistent accounting policies as those adopted in the financial statements for the year ended 31 March 2025.
The interim consolidated financial statements are prepared in sterling, which is the functional currency of the group. Monetary amounts in these interim consolidated financial statements are rounded to the nearest £1.
The financial statements have been prepared on the historical cost basis, modified to include the revaluation of certain financial instruments at fair value.
2.2 Basis of consolidation
The Group financial statements consolidates those of the parent company and the subsidiaries of which the parent has control, together with the Employee Benefit Trust. Control is established when the parent is exposed, or has rights, to variable returns from its involvement with the subsidiary and has the ability to affect those returns through its power over the subsidiary.
Where a subsidiary undertaking is acquired/disposed of during the year, the consolidated profits or losses are recognised from/until the effective date of the acquisition/disposal, being the date on which control is obtained or lost.
All inter-company balances and transactions between group companies have been eliminated on consolidation.
Where necessary, adjustments are made to the financial information of subsidiaries to bring the accounting policies used into line with those used by the Group.
2.3 Going concern
The financial statements have been prepared on a going concern basis. The Directors have reviewed and considered relevant information, including the annual budget and future cash flows in making their assessment. The Directors have tested their cash flow analysis to take into account the impact on their business of possible scenarios, alongside the measures that they can take to mitigate the impact of possible downside scenarios. Based on these assessments, given the measures that could be undertaken to mitigate the current adverse conditions, and the current resources available, the Directors have concluded that they can continue to adopt the going concern basis in preparing the annual report and accounts.
2.4 Revenue
Revenue
One Health Group applies IFRS 15 'Revenue from contracts with customers'. Under IFRS 15, One Health Group applies the 5-step method to identify contracts with its customers, determine performance obligations arising under those contracts, set an expected transaction price, allocate that price to the performance obligations, and then recognises revenues as and when those obligations are satisfied.
Provision of medical and clinical services, specialist treatments and diagnostics
Service revenue is recognised in accordance with the discharge of performance obligations to the customer by each treatment, consultation or operation. Value and control are transferred when surgery, consultation or other medical procedures are performed, which means that revenue is recognised at a point in time on the day in which the treatment, consultation or operation occurs.
Sale of medical implants
Knee replacements are supplied to surgeons under contracts where the key performance criteria for One Health Group are the provision of such implants for the provision of their services. The fair value of the revenue, being the price per unit net of volume discounts and sales taxes, is recognised as revenue at the point of transfer of control to the customer. Control transfers at the point of physical delivery to the medical facility. As can be seen in the revenue note, this not a numerically large element of the business.
Private practice
Other partners in the LLPs also provide private medical services to their own patients. These are arranged through the LLPs as agent, so only the Group's commission is included in revenue.
3. Adjusted EBITDA
The consolidated income statement has presented adjusted earnings before interest, tax, depreciation, and amortisation, and the revaluation of investment property ("EBITDA"). It further presents "Adjusted EBITDA" which is EBITDA but further removing additional non-cash and non-recurring items including share-based payments, discretionary bonus payments by the EBT to employees and directors, and other non-recurring costs as a group, which are not relevant to the underlying cash generation of the business.
The EBT-settled employee bonuses are shown separately on the grounds that these are paid from restricted cash, subject to approval by the EBT trustees as opposed to the Group itself, and are paid based on the performance of the Group by reference to EBITDA.
4. Earnings per share
The calculation of the basic and diluted earnings per share is based on the following data:
Earnings
6 months ended 30 September 2025 UNAUDITED
6 months ended 30 September 2024 UNAUDITED
Year ended 31 March 2025 AUDITED
£
£
£
Earnings for the purpose of basic earnings per share being net profit attributable to owners of the parent
945,255
664,403
1,064,415
Earnings for the purposes of diluted earnings per share
945,255
664,403
1,064,415
Number of shares
6 months ended 30 September 2025 UNAUDITED
6 months ended 30 September 2024 UNAUDITED
Year ended 31 March 2025 AUDITED
£
£
£
Weighted average number of ordinary shares for the purposes of basic earnings per share
13,709,615
9,573,027
10,645,311
- Number of diluting share options
198,821
181,133
181,133
- Number of diluting warrants
35,074
19,750
19,750
Weighted average number of ordinary shares for the purposes of diluted earnings per share
13,943,510
9,773,910
10,846,194
Earnings per share
Earnings
6 months ended 30 September 2025 UNAUDITED
6 months ended 30 September 2024 UNAUDITED
Year ended 31 March 2025 AUDITED
Pence per weighted average shares
6.89p
6.94p
10.00p
Pence per weighted average diluted shares
6.78p
6.80p
9.81p
Adjusted earnings per weighted average shares
6.89p
7.46p
13.75p
Adjusted Earnings per share
The Directors use adjusted earnings as a key measure, as detailed in note 3. The calculated adjusted earnings per share is shown above on this basis.
Adjusted Earnings per Share
6 months ended 30 September 2025 UNAUDITED
6 months ended 30 September 2024 UNAUDITED
Year ended 31 March 2025 AUDITED
£
£
£
Profit/(loss) after taxation
945,255
664,403
1,064,415
Adjusted for:
Non-recurring costs
-
50,030
399,796
Adjusted Earnings
945,255
714,433
1,464,211
Pence per weighted average shares
6.89p
7.46p
13.75p
Pence per weighted average diluted shares
6.78p
7.31p
13.50p
5. Property, plant and equipment
Freehold land and buildings £
Assets under construction £
Plant and machinery £
Fixtures and fittings £
Computer equipment £
Total £
Cost
At1 April 2025
876,097
294,936
54,052
104,084
394,138
1,723,307
Additions
563,153
944,332
45,120
-
37,756
1,590,361
Disposals
-
-
-
-
(8,909)
(8,909)
At 30 September 2025
1,439,250
1,239,268
99,172
104,084
422,985
3,304,759
Amortisation and impairment
At1 April 2025
103,959
-
18,453
31,347
189,690
343,449
Amortisation charged for the period
17,530
-
5,000
5,204
37,404
65,138
Eliminated on disposals
-
(8,582)
(8,582)
At 30 September 2025
121,489
-
23,453
36,551
218,512
400,005
Carrying amount
At30 September 2025
1,317,761
1,239,268
75,719
67,533
204,473
2,904,754
At31 March 2025
772,138
294,936
35,599
72,737
204,448
1,379,858
In the period, one apartment at Psalter Lane that had been held as investment property was renovated into office space for company use. The valuation of property transferred was calculated using a percentage of floor space and weighted accordingly.
Within additions to assets under construction is a purchase of land totalling £682,263 and construction costs of £262,069 for the Scunthorpe surgical facility. Land will not be depreciated, whilst other construction costs will not be depreciated until the facility is brought into use.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
IR BUBDBRDDDGUI
